|
1
|
Martins C, Sousa P, Araújo T, Castro-Poças
F and Pedroto I: Mediastinal mass in a patient with colorectal
cancer: A diagnostic challenge. GE Port J Gastroenterol.
24:193–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cermak K, Thill V, Simoens CH, Smets D,
Ngongang CH and da Costa PM: Surgical resection for colon cancer:
laparoscopic assisted vs. open colectomy. Hepatogastroenterology.
55:412–417. 2008.PubMed/NCBI
|
|
3
|
Heo JH, Ryu CG, Jung EJ, Paik JH and Hwang
DY: Clinical significance of preoperative virtual colonoscopy for
evaluation of the proximal colon in patient with obstructive
colorectal cancer. Ann Coloproctol. 33:130–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wicha MS: Targeting self-renewal, an
Achilles' heel of cancer stem cells. Nat Med. 20:14–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiricny J: The multifaceted
mismatch-repair system. Nat Rev Mol Cell Biol. 7:335–346. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iyer RR, Pluciennik A, Burdett V and
Modrich PL: DNA mismatch repair: Functions and mechanisms. Chem
Rev. 106:302–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barberán S, Fraguas S and Cebrià F: The
EGFR signaling pathway controls gut progenitor differentiation
during planarian regeneration and homeostasis. Development.
143:2089–2102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saafan H, Foerster S, Parra-Guillen ZP,
Hammer E, Michaelis M, Cinatl J Jr, Völker U, Fröhlich H, Kloft C
and Ritter CA: Utilising the EGFR interactome to identify
mechanisms of drug resistance in non-small cell lung cancer - proof
of concept towards a systems pharmacology approach. Eur J Pharm
Sci. 94:20–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Y, Zhou H, Chen A, Pittman RN and
Field J: The Akt proto-oncogene links Ras to Pak and cell survival
signals. J Biol Chem. 275:9106–9109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trojan J, Mineur L, Tomášek J, Rouleau E,
Fabian P, de Maglio G, García-Alfonso P, Aprile G, Taylor A,
Kafatos G, et al: Panitumumab use in metastatic colorectal cancer
and patterns of KRAS testing: Results from a Europe-wide physician
survey and medical records review. PLoS One. 10:e01407172015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu J, Yan WY, Xie L, Cheng L, Yang M, Li
L, Shi J, Liu BR and Qian XP: Coexistence of MSI with KRAS mutation
is associated with worse prognosis in colorectal cancer. Medicine
(Baltimore). 95:e56492016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sideris M and Papagrigoriadis S: Molecular
biomarkers and classification models in the evaluation of the
prognosis of colorectal cancer. Anticancer Res. 34:2061–2068.
2014.PubMed/NCBI
|
|
14
|
Slik K, Kurki S, Korpela T, Carpén O,
Korkeila E and Sundström J: Ezrin expression combined with MSI
status in prognostication of stage II colorectal cancer. PLoS One.
12:e01854362017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shemirani AI, Haghighi MM, Milanizadeh S,
Taleghani MY, Fatemi SR, Damavand B, Akbari Z and Zali MR: The role
of kras mutations and MSI status in diagnosis of colorectal cancer.
Gastroenterol Hepatol Bed Bench. 4:70–75. 2011.PubMed/NCBI
|
|
18
|
Vilar E and Gruber SB: Microsatellite
instability in colorectal cancer-the stable evidence. Nat Rev Clin
Oncol. 7:153–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Philip P, Ernst P and Wantzin GL:
Karyotypes in infectious mononucleosis. Scand J Haematol.
15:201–206. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kambara T, Simms LA, Whitehall VL, Spring
KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara
N, et al: BRAF mutation is associated with DNA methylation in
serrated polyps and cancers of the colorectum. Gut. 53:1137–1144.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN and
Shi XY: KRAS and BRAF gene mutations and DNA mismatch repair status
in Chinese colorectal carcinoma patients. World J Gastroenterol.
21:1595–1605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Omidifar N, Geramizadeh B and Mirzai M:
K-ras mutation in colorectal cancer, a report from Southern Iran.
Iran J Med Sci. 40:454–460. 2015.PubMed/NCBI
|
|
23
|
Fujiyoshi K, Yamamoto G, Takahashi A, Arai
Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto
H, et al: High concordance rate of KRAS/BRAF mutations and MSI-H
between primary colorectal cancer and corresponding metastases.
Oncol Rep. 37:785–792. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinetti D, Costanzo R, Kadare S,
Alimehmeti M, Colarossi C, Canzonieri V, Berretta M and Memeo L:
KRAS and BRAF mutational status in colon cancer from Albanian
patients. Diagn Pathol. 9:1872014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawazoe A, Shitara K, Fukuoka S, Kuboki Y,
Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, et al: A
retrospective observational study of clinicopathological features
of KRAS NRAS, BRAF and PIK3CA mutations in Japanese patients with
metastatic colorectal cancer. BMC Cancer. 15:2582015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogura T, Kakuta M, Yatsuoka T, Nishimura
Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y and Akagi K:
Clinicopathological characteristics and prognostic impact of
colorectal cancers with NRAS mutations. Oncol Rep. 32:50–56. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamane LS, Scapulatempo-Neto C, Alvarenga
L, Oliveira CZ, Berardinelli GN, Almodova E, Cunha TR, Fava G,
Colaiacovo W, Melani A, et al: KRAS and BRAF mutations and MSI
status in precursor lesions of colorectal cancer detected by
colonoscopy. Oncol Rep. 32:1419–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fleming M, Ravula S, Tatishchev SF and
Wang HL: Colorectal carcinoma: Pathologic aspects. J Gastrointest
Oncol. 3:153–173. 2012.PubMed/NCBI
|
